Under one in 10 patients who could benefit from obesity jabs such as Wegovy are able to get them, caution the World Health Organization as it publishes its inaugural advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is advocating for increased and just access to these injectable treatments.
Per estimates, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The new guidance recognises that excess weight is a chronic disease that can be treated with thorough and ongoing support," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant obstacles to universal access to the jabs that can aid individuals in losing significant body mass, says the organization.
Weight-Loss Drug Supply Crisis
Despite the current most favorable case, the manufacturing of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, per the health organization.
The recommendation urges governments and firms to widen access, through strategies like patent sharing.
A patent on semaglutide – the core ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Drugs Operate
The injections replicate a biological compound to reduce digestion speed, reduce hunger and increase satiety so individuals eat less.
People typically begin shedding pounds within a few weeks of starting on the weekly injections.
Studies points to people may regain a significant portion after a year of discontinuing the treatment, when their usual appetite resume.
Being above a healthy weight elevates your likelihood for experiencing health problems, such as type 2 diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns individuals in every country and was responsible for millions of fatalities worldwide in 2024, according to the health agency.
